|
(1) | Application for a product licence for — |
|
| | |
(a) | a medicinal product that has not yet been approved by any competent drug regulatory agency and is therefore required by the Authority to undergo full evaluation: |
|
| | |
(i) | application fee for the initial screening# |
|
| | |
| | |
(b) | a medicinal product that has been approved by at least one competent drug regulatory agency and is therefore allowed by the Authority to undergo abridged evaluation: |
|
| | |
(i) | application fee for the initial screening# |
|
| | |
(ii) | evaluation fee* for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(iii) | evaluation fee* for each subsequent product in a series of products of different strengths |
|
| | |
(c) | a medicinal product that has been approved by a reference drug regulatory agency and is therefore allowed by the Authority to undergo verification evaluation: |
|
| | |
(i) | application fee for the initial screening# |
|
| | |
(ii) | evaluation fee* for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(iii) | evaluation fee* for each subsequent product in a series of products of different strengths |
|
| | |
| | |
(a) | the first year of the term of a product licence |
|
| | |
(b) | each subsequent year of the term of a product licence |
|
| | |
(3) | Application to amend a product licence — |
|
| | |
(a) | to make a major variation, where the application is required to undergo full evaluation by the Authority: |
|
| | |
(i) | application fee for the initial screening# |
|
| | |
| | |
(b) | to make a major variation, where the application can be reviewed by the Authority through abridged evaluation: |
|
| | |
(i) | application fee for the initial screening# |
|
| | |
(ii) | evaluation fee* for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(iii) | evaluation fee* for each subsequent product in a series of products of different strengths |
|
| | |
(c) | to make a major variation, where the application can be reviewed by the Authority through verification evaluation: |
|
| | |
(i) | application fee for the initial screening# |
|
| | |
(ii) | evaluation fee* for a single‑strength product or the first product in a series of products of different strengths |
|
| | |
(iii) | evaluation fee* for each subsequent product in a series of products of different strengths |
|
| | |
(d) | to make any other variations to the product specifications of a medicinal product: |
|
| | |
| | |
| | |
2. | IMPORT LICENCE (INCLUDING FOR CHINESE PROPRIETARY MEDICINES) |
|
| | |
(1) | Application fee for an import licence |
|
| | |
| | |
(a) | the first year of the term of an import licence |
|
| | |
(b) | each subsequent year of the term of an import licence |
|
| | |
(3) | Application fee to amend an import licence — |
|
| | |
| | |
(b) | without site inspection^ |
|
| | |
3. | WHOLESALE DEALER’S LICENCE (INCLUDING FOR CHINESE PROPRIETARY MEDICINES) |
|
| | |
(1) | Application fee for a wholesale dealer’s licence |
|
| | |
| | |
(a) | the first year of the term of a wholesale dealer’s licence |
|
| | |
(b) | each subsequent year of the term of a wholesale dealer’s licence |
|
| | |
(3) | Application fee to amend a wholesale dealer’s licence — |
|
| | |
| | |
(b) | without site inspection^ |
|
| | |
4. | MANUFACTURER’S LICENCE (INCLUDING FOR CHINESE PROPRIETARY MEDICINES) |
|
| | |
(1) | Application fee for a manufacturer’s licence for — |
|
| | |
(a) | manufacture of external preparations only |
|
| | |
(b) | manufacture of oral preparations only |
|
| | |
(c) | manufacture of external and oral preparations only |
|
| | |
(d) | manufacture of sterile preparations, or other types of dosage forms or dosage form combinations not described in sub‑paragraphs (a), (b) and (c), if the medicinal product is not a Chinese proprietary medicine |
|
| | |
(e) | primary assembly of a medicinal product |
|
| | |
(f) | secondary assembly of a medicinal product |
|
| | |
| | |
(a) | the first year of the term of a manufacturer’s licence |
|
| | |
(b) | each subsequent year of the term of a manufacturer’s licence for — |
|
| | |
(i) | manufacture of external preparations only |
|
| | |
(ii) | manufacture of oral preparations only |
|
| | |
(iii) | manufacture of external and oral preparations only |
|
| | |
(iv) | manufacture of sterile preparations, or other types of dosage forms or dosage form combinations not described in sub-paragraphs (i), (ii) and (iii), if the medicinal product is not a Chinese proprietary medicine |
|
| | |
(v) | primary assembly of a medicinal product |
|
| | |
(vi) | secondary assembly of a medicinal product |
|
| | |
(3) | Application fee to amend a manufacturer’s licence — |
|
| | |
(a) | with site inspection^ (for a licence to manufacture a medicinal product) |
|
| | |
(b) | with site inspection^ (for a licence to assemble a medicinal product) |
|
| | |
(c) | without site inspection^ |
|
| | |
5. | CERTIFICATES AND DOCUMENTS (NON‑MANDATORY) |
|
| | |
(1) | Application fee for a Certificate to Export a Medicinal Product |
|
| | |
(2) | Application fee for a Certificate to Export a Chinese Proprietary Medicine |
|
| | |
(3) | Application fee for a Confirmation of Authorisation to Import a Psychotropic Substance |
|
| | |
(4) | Application fee for a Confirmation of Authorisation to Import a Restricted Substance |
|
| | |
|
# | Fee is payable upon submission of application. |
|
|
* | Fee is payable upon acceptance of application. |
|
|
^ | Refer to the Authority’s guidance notes on amendment applications for licences (available at the Authority’s website) to find out if a site inspection is required. |
|
|